Skip to main content

Cinryze News

FDA Approves Haegarda - First Subcutaneous C1 Esterase Inhibitor for Hereditary Angioedema

June 22, 2017 – The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Cinryze patient information at Drugs.com